Qt Imaging Holdings, Inc. · NASDAQ:QTI
Qt Imaging — Investor Presentation (April 2024)
42 slides from Qt Imaging's investor presentation, April 2024
Slide 1: Quantitative Transmission Imaging Investor Presentation
Quantitative Transmission Imaging Breast Acoustic CT™ Scanner INVESTOR PRESENTATION April 2024
Slide 2: Disclaimer
Disclaimer ABOUT THIS PRESENTATION This investor presentation (this “Presentation”) is provided for informational purposes only. The information contained herein does not purport to be all-inclusive and neither QT Imaging Holdings, Inc. (the “Company”, “QT Imaging Holdings”, “QTI”), nor its respecti
Slide 3: Disclaimer: Forward Looking Statements
Disclaimer FORWARD LOOKING STATEMENTS Certain statements included in this Presentation that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generall
Slide 4: QT Imaging Holdings Has the Potential to Transform Medical Imaging
QT Imaging Holdings (QTI) Has the Potential to Transform Medical Imaging • QTI is a medical device company with imaging technology that has the potential to transform the industry • QTI Scanner is the only 3D imaging device to receive FDA clearance for use as a transmission and reflection ultrasonic
Slide 5: QT Imaging Holdings Has the Potential to Transform Medical Imaging
QT Imaging Holdings (QTI) Has the Potential to Transform Medical Imaging • This sub-millimeter, high-definition, image resolution enables the identification of normal and abnormal breast structures and the accurate depiction and measurement of the precise shape and location of findings, as well as b
Slide 6: Introduction to the QT Imaging Holdings Management Team
Introduction to the QT Imaging Holdings Management Team Nasser C. Bilal Malik, Dr. Raluca Dinu Stas Budagov Steve Choate Pirshafiey, MBA Ph.D. CHIEF EXECUTIVE CHIEF FINANCIAL CHIEF OPERATING CHIEF PRODUCT CHIEF SCIENCE OFFICER OFFICER OFFICER OFFICER OFFICER Dr. Raluca Dinu is a global Mr. Budagov i
Slide 7: Our Mission
Our Mission • Create disruptive innovation—a dedication to using technology (software, artificial intelligence, and smart physics) to improve medical imaging and thus health care quality and access • Continue to improve our FDA-cleared, high quality, high resolution, native NIH has awarded 3D, repro
Slide 8: Executive Summary
Executive Summary • Low-cost, comprehensive, quantitative, no radiation • Patent-protected technology: medical imaging solution yielding sub-millimeter, 14 granted US/Europe high-definition, image resolution: application in areas − Software platform protected by trade secrets such as breast • infant
Slide 9: QTI's Technology Has the Opportunity to Transform Several Large Markets
QTI’s Technology Has the Opportunity to Transform Several Large Markets 2022 GLOBAL MEDICAL IMAGING MARKET SIZE: $29B(1) Current Market Future Markets – Body Scanner Platform Development IMAGE-GUIDED PROCEDURES: BREAST: $5B MARKET(2) ORTHO: $9B MARKET(3) INFANT: $8B MARKET (4) $5B MARKET(5) • FDA ap
Slide 10: Agreement Signed with NXC Imaging
Agreement Signed with NXC Imaging A Subsidiary of Canon Medical Systems • Sales Agent Agreement signed with NXC Imaging marks a major milestone for QTI • Accessing NXC Imaging's distribution channel in the US and the US territories, this agreement provides potential to accelerate the commercial roll
Slide 11: Feasibility Study Agreement Signed with Canon Medical Systems
Feasibility Study Agreement Signed with Canon Medical Systems • Canon to initiate studies to evaluate the business, technical, and clinical values of QTI’s ultrasound breast scanner including: − product quality validation − development and manufacturing studies − clinical evaluation − regulatory inv
Slide 12: Technology Overview
bo QT IMAGING TECHNOLOGY OVERVIEW
Slide 13: Current Ultrasound Technologies Have Major Deficiencies
Current Ultrasound Technologies Have Major Deficiencies Shortfalls of Commercial Current, Rival Systems(2): • Reflection images have speckle; compounding without refraction correction • No valid true “transmission” mode – use “shear wave” (low resolution) data (ABUS, AVUS, etc. are not transmission)
Slide 14: Critical Modality Advantages of QTI's Breast Acoustic CT
Critical Modality Advantages of QTI’s Breast Acoustic CT(1) • Clinically useful sensitivity and specificity • Presence of comparative clinical trials • Proven success in head-to-head trials against mammography for primary screening • Ability to determine doubling times – can identify slow growing ca
Slide 15: Why QTI Scan Generates Better Resolution Compared to MRI
Why QTI Scan Generates Better Resolution Compared to MRI: More Data! MRI Spiral data QTI (3D UT) Planar acquisition Volumetric 20mm for speed of overlapping acquisition detectors 2mm gap Receiver Array Receiver Array Data points per voxel ~200,000 Data points per voxel times more data ~180 thousand
Slide 16: Market Positioning of Breast Acoustic CT Scanner
Market Positioning of Breast Acoustic CT Scanner • Not intended to compete with mammography for screening, although many patients may find it preferrable for: − Dense breasts − Implants − Post therapy screening where breasts can be very sensitive to compression − When concerned about radiation dose
Slide 17: Technical Capabilities
Technical Capabilities • Resolution of ~600 microns in reflection compared to 800 microns(1) for MRI (depends on field strength, homogeneity etc) • Contrast to noise ratio of 23:1 at 100 microns ( in reflection; can detect small calcifications) • Contrast to noise ratio of 15:1 (at resolution in tra
Slide 18: Enhanced Clinical Capabilities and Value
Enhanced Clinical Capabilities and Value • High-quality and high-resolution native 3D Imaging • Quantifiable images enables accurate analysis, comparison and trending • Consistent and reproduceable image quality regardless of operator or breast size/tissue type. • Clinical feature detection of 50-10
Slide 19: Resolution and Detectability: MRI vs QTI's Acoustic CT
Resolution and Detectability: MRI vs QTI’s Acoustic CT (3D UT) MRI QTI’s Acoustic CT MRI Alveoli image of a piglet lung MRI resolution depends Higher resolution than QTI’s Acoustic CT (3D UT) on acquisition time, 3T MRI in air-filled organs with reflection mode B1 inhomogeneity, etc. • Resolution is
Slide 20: Bovine Eye: Reflection, ex vivo
Bovine Eye: Reflection, ex vivo Optic Double Cell Layer Nerve of Cornea Separation is 800 Microns Retinal and Thickness Subretinal Space ~100 Microns Copyright ©2024 QT Imaging, Holdings, Inc. All Rights Reserved. 20
Slide 21: Bovine Eye: Speed of Sound, ex vivo
Bovine Eye: Speed of Sound, ex vivo Lens 1667 m/s Iris 1551 m/s Connective Tissue Cellular Tissue Vitreous Humor Aqueous 1488 m/s 1506 m/s Fat Cornea 1480 m/s 1562 m/s Copyright ©2024 QT Imaging, Holdings, Inc. All Rights Reserved. 21
Slide 22: Breast Health
bo QT IMAGING BREAST HEALTH
Slide 23: QT Imaging's FDA-cleared Solution for Dense Breasts
QT Imaging’s FDA-cleared Solution for Dense Breasts Many Women Have Dense Breasts, The FDA Has Recognized the Which Mammograms are Inefficient Importance of Breast Density in Screening for Cancer in Breast Cancer Screening 50% of women between 50% 50% the ages of 40-74 in the US have dense breasts(1
Slide 24: Clinical Trials: Dense Breast Imaging Studies
CLINICAL TRIALS: Dense Breast Imaging Studies Using DBT Show Sensitivity Close to 40%(3) Approximately 50% of women between the ages of 40-74 in the US have dense breasts(1), with traditional mammography missing 35.6-52.2% of breast cancers in dense breast tissue(2) making QT Scanner the only system
Slide 25: Other Ultrasound Products Use 2D Imaging for Dense Breast Screening
Other Ultrasound Products Use 2D Imaging for Dense Breast Screening DELPHINUS BREAST INVENIA ABUS ACUSON S2000 ABVS AWBUS SOFIA 3D SOFTVUE ACOUSTIC CT DESIGN TYPE Articulating Arm Articulating Arm Articulating Arm Rotating Armature Water Bath Water Bath Guided Handheld OUTPUT Stacked 2D Stacked 2D S
Slide 26: The Current Breast Imaging Paradigm Leads to Unnecessary Concern and Costs
The Current Breast Imaging Paradigm Leads to Unnecessary Concern and Costs Screening compliance is low For every 1,000 screening mammograms: 35% of women aged 40–70 35% do not get screened.(1) CALL BACK RATES 98% of 65% Do not follow guidelines ~15% call-backs rates with 150 Recalls are Avoidable Fo
Slide 27: Current and Future Uses of QT Breast Scanner
Current and Future Uses of QT Breast Scanner The QT Breast Scanner has been granted FDA clearances that allow for meaningful clinical use, with potential for a future roadmap to provide a replacement to screening mammography, a transformational milestone that would significantly expand the market op
Slide 28: Current and Future Uses of QT Breast Scanner
Current and Future Uses of QT Breast Scanner The QT Breast Scanner has been granted FDA clearances that allow for meaningful clinical use, with potential for a future roadmap to provide a replacement to screening mammography, a transformational milestone that would significantly expand the market op
Slide 29: QTI Offers Potential Capabilities for Screening, Diagnosis, and Monitoring
QTI Offers Potential Capabilities for Screening, Diagnosis, and Monitoring SUPPLEMENTAL SCREENING • Supplementary screening (Approved) DIAGNOSIS − Dense Breasts • Quantification of − Intermediate to high-risk women MONITORING fibroglandular volume − Implants (Approved) • Primary screening for mammog
Slide 30: The QT Scanner Delivers a Better Experience for Patients
The QT Scanner Delivers a Better Experience for Patients than Traditional Systems HANDHELD QT IMAGING ULTRASOUND MRI MAMMOGRAPHY Image Quality Safety(1) Speed Cost Efficiency Patient Experience …OVER HHUS …OVER MRI ...OVER MAMMOGRAPHY The QTI • Superior image quality • High resolution and • Improved
Slide 31: QTI Clinical Trials Provide Compelling Results for Adoption and Approvals
QTI Clinical Trials Provide Compelling Results for Adoption and Approvals IMPLICATION OF RESULTS OR CLINICAL TRIALS PRELIMINARY RESULTS • Visual Grading Assessment of Quantitative Transmission Ultrasound Compared to Digital X-ray Mammography and Hand-held Ultrasound QT can see more anatomy than mamm
Slide 32: Two Clinical Trials Completed and Published
Two Clinical Trials Completed and Published QT Performance Relative To FFDM and DBT in Mass Detection STUDY #2 (Comparison to STUDY #1 FFDM Digital Breast Tomosynthesis) VS In recent studies, QT outperformed today’s gold standard (Digital Breast Tomosynthesis) (1) Study #1: An Exploratory Multi-read
Slide 33: Clinical Adoption
bo QT IMAGING CLINICAL ADOPTION
Slide 34: Key Milestones Have Been Achieved
Key Milestones Have Been Achieved With Additional Catalysts to Drive Commercial Adoption and Increased Market Share Breast Acoustic CT™ System 18 months Key Milestones Achieved for Commercial Adoption üFour placements in North America to date and more on the way üSigned Sales Agent Agreement with NX
Slide 35: Reimbursement Will Be Driven by the Value and Savings Provided to Patients
Reimbursement Will Be Driven by the Value and Savings Provided to Patients EXISTING FUTURE • CPT codes, non-specific to • CPT code specific to QT Scanner® QTI technology: − Higher reimbursements capture full value − Unilateral or Bilateral breast ultrasound of unique advantages that QT Scans offer (
Slide 36: Open Angle Scanner
bo QT IMAGING OPEN ANGLE SCANNER
Slide 37: Developing an Open Angle Scanner Will Expand the Technology to New Markets
Developing an Open Angle Scanner Will Expand the Technology to New Markets Development of the open angle scanner is underway… • QTI has successfully completed feasibility studies for partial angle reconstruction • QTI has verified the ability to perform data acquisition and image reconstruction with
Slide 38: Developing an Open Angle Scanner Will Expand the Technology to New Markets
Developing an Open Angle Scanner Will Expand the Technology to New Markets …providing significant potential to access new markets and applications • The Open Angle Scanner uses an open, partial angle configuration which reduces the viewing field from 3600 to 3250 and provides additional capabilities
Slide 39: The Infrastructure is in Place to Allow for the Rollout of the Next Generation Scanner
The Infrastructure is in Place to Allow for the Rollout of the Next Generation Scanner Next Generation Open Angle Scanner Key Infrastructure in Place for Development üUnderlying ultra-low frequency sound emitting technology üInitial Proof of Concept üCommencement of prototype design and build Upcomi
Slide 40: Open Angle Scanner Development Pathway and Corresponding Catalysts
Open Angle Scanner Development Pathway and Corresponding Catalysts Open Angle Proof of Prototype Design & Build Hardware Concept (First Clinical Trials) Development Ortho Software Software Submitted Development Development w/Hardware Rollout (First Clinical Trials) (FDA Clearance) Software Infant So
Slide 41: Investment Highlights
Investment Highlights Cutting-edge imaging technology with multiple potential applications creates a tremendous opportunity to transform the imaging market NXC Imaging Agreement to Drive Accelerated Industry-Transforming Commercial Roll-out Imaging Technology Platform Recognized by Feasibility Study
Slide 42: Thank You!
bo QT IMAGING Thank You!
QT Imaging Holdings — Investor Presentation (April 2024) on 6ix